Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency
Phase 3
Completed
- Conditions
- Venous Insufficiency
- Interventions
- Drug: Antistax®Drug: Placebo
- Registration Number
- NCT02191254
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Study to assess the efficacy and tolerability of Antistax® film-coated tablets in patients with chronic venous insufficiency (CVI, Clinical condition, Etiology, Anatomic location, Pathophysiology (CEAP) Classification: Clinical Class 3, or 4a)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 245
Inclusion Criteria
- Male or female
- 18 years of age or older
- CVI, Clinical Class 3 (oedema) or 4a (mild skin changes ascribed to venous disease, e.g. pigmentation), according to the CEAP classification
- Willing and able to give written informed consent prior to participation in the study
Exclusion Criteria
Concomitant diseases:
- Decompensated cardiac insufficiency
- Oedema not due to venous disease of the legs (e.g., latent cardiac insufficiency, renal insufficiency, lymphoedema, etc)
- Peripheral arterial disease (ankle/arm pressure index < 0.9)
- Current acute phlebitis or thrombosis
- Renal insufficiency (serum creatinine > 1.5 mg/dl)
- Liver disease (SGPT > 3x upper limit of normal)
- Other diseases: hyper- or hypocalcaemia, malignancies
- Anamnestic indications of diabetic microangiopathy or polyneuropathy
- Drug and/or alcohol abuse
- Severe climacteric complaints: changes in, or initiation with post-menopausal hormone replacement therapy within the last 3 months
- Immobility
- Avalvulia
- Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
- State after pulmonary embolism
- Recognised hypersensitivity to the trial drug ingredients
- Current florid venous ulcus
- Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compression treatment, phlebectomy, etc.
Previous treatments:
- Patients who are on compression therapy and/or are wearing support stockings and who optimally benefit from these measures
- Treatment with venous drugs within the last 2 weeks prior to the intake of study medication
- Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors, calcium antagonists, or laxatives within the last 2 weeks prior to the intake of study medication
Concomitant treatment/non-drug therapy exclusion criteria:
- Other venous drugs apart from the trial medication
- Venous surgery or sclerotherapy within the last 12 month at the leg used for volumetry
- Extensive use of laxatives
- Major surgery requiring full anaesthesia
Other exclusion criteria:
- Previously studied under this protocol
- Participation in another clinical trial within the previous 90 days or during the present study
- Patient is investigator, co-investigator, or study nurse in this study
- Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
- Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
- Patients in a bad general health state according to the investigator's judgement
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Antistax® Antistax® 1 tablet per day for 12 weeks Placebo Placebo -
- Primary Outcome Measures
Name Time Method Change from baseline in limb volume determination Baseline, day 84 water displacement method
- Secondary Outcome Measures
Name Time Method Global assessment of tolerability by the patient on a 4-point VRS day 84 Number of patients with adverse events up to 12 weeks Changes in limb volume determination Baseline, day 21 and day 42 water displacement method
Changes in the calf circumference Baseline, at day 21, 42 and 84 in centimeters
Changes in the ankle circumference Baseline, at day 21, 42, and 84 in centimeters
Changes in the subjective symptoms of CVI measured by Visual Analogue Scales (VAS) Baseline, at day 21, 42, and 84 Global assessment of efficacy by the patient on a 4-point verbal rating scale (VRS) day 84 Global assessment of efficacy by the investigator on a 4-point VRS day 84 Global assessment of tolerability by the investigator on a 4-point VRS Day 84 Number of patients with clinically significant changes in laboratory values Baseline, week 12 Number of patients with clinically significant changes in vital signs (Blood Pressure (BP), Pulse Rate (PR)) Baseline, up to 12 weeks